Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Time to fix the price fix.

A Earl-Slater¹

¹Keele University, UK.

The Health Service Journal

|October 9, 1997

Summary

The UK's pharmaceutical price regulation scheme shows no evidence of effectiveness and is considered flawed. Alternatives like regional drugs committees should be explored, with government consultation before any changes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Donepezil and Alzheimer's dementia.

Clinical performance and quality health care·2001

Same author

Digest of evidence ... pramipexole and Parkinson's disease.

Clinical performance and quality health care·2001

Same author

An integrated national pharmaceutical policy for the United Kingdom?

BMJ (Clinical research ed.)·2000

Same author

Clinical guidelines. Nice work: spell it out for me.

The Health service journal·2000

Same author

Pharmaceuticals. Plunder and pillage.

The Health service journal·1999

Same author

Where is scientific evidence supporting EU policy on BSE and pharmaceuticals?

BMJ (Clinical research ed.)·1998

Area of Science:

Health economics
Pharmaceutical policy
Public health

Background:

The current pharmaceutical price regulation scheme in the UK is under scrutiny.
Concerns exist regarding its suitability for the modern National Health Service (NHS).
Potential flaws and ineffectiveness have been raised as arguments for its abolition.

Purpose of the Study:

To evaluate the effectiveness of the UK's pharmaceutical price regulation scheme.
To explore arguments for abolishing the current scheme.
To identify and propose suitable alternatives for pharmaceutical pricing and regulation.

Main Methods:

Review of existing evidence on the pharmaceutical price regulation scheme.
Analysis of arguments for and against the scheme.
Examination of alternative models, such as regional drugs committees.

Main Results:

No evidence found to support the effectiveness of the current UK pharmaceutical price regulation scheme.
The scheme is considered seriously flawed and inappropriate for the current health service.
Alternative models, including evidence-based regional drugs committees, are proposed.

Conclusions:

The UK's pharmaceutical price regulation scheme is not demonstrably working and should be reconsidered.
The government should investigate alternative approaches, such as regional drugs committees.
Consultation with healthcare professionals and the public is recommended before implementing changes to pharmaceutical pricing policy.

Related Experiment Videos